Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 10/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 10/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 10/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 10/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 2/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.45 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29437788 | 1.00 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 | |
| SCHEMBL20555598 | 0.96 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 | |
| SCHEMBL5770288 | 0.96 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 | |
| SCHEMBL18797648 | 0.96 | MAPK13 (1.00) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 | |
| Hydrochloric Acid SCHEMBL5768856 | 0.94 | MAPK13 (0.97) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 | |
| Bromide SCHEMBL5770111 | 0.94 | MAPK13 (0.97) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 | |
| SCHEMBL5767876 | 0.89 | MAPK13 (0.87) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 | |
| SCHEMBL5770557 | 0.88 | MAPK13 (0.85) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 | |
| SCHEMBL5771142 | 0.88 | MAPK13 (0.84) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 | |
| SCHEMBL5772600 | 0.87 | MAPK11 (0.82) | MAPK13MAPK12MAPK11MAPK14CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4717765-A1 | METHOD FOR PRODUCING CELL POPULATION CONTAINING CD4 SINGLE POSITIVE HELPER T CELLS FROM PLURIPOTENT STEM CELLS | Kyoto University (JP) | 2026-04-01 | — | — | EP | disclosed |
| EP-3445369-B1 | VX-745 FOR USE IN THE TREATMENT OF DEMENTIA | EIP PHARMA LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20250333470-A1 | METHOD FOR PRODUCING GAMMA DELTA T CELLS | UNIV KYOTO (JP) | 2025-10-30 | — | — | US | disclosed |
| US-12391739-B2 | Method for producing gamma delta T cells | KYOTO UNIVERSITY (JP) | 2025-08-19 | — | — | US | disclosed |
| EP-4596685-A1 | IMMUNE CELL INDUCED FROM IPS CELL | Kyoto University (JP) | 2025-08-06 | — | — | EP | disclosed |
| US-12351824-B2 | Method for producing natural killer cells from pluripotent stem cells | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-08 | — | — | US | disclosed |
| US-20250177524-A1 | CELL BANK COMPOSED OF IPS CELLS FOR INTRODUCING T CELL RECEPTOR GENE | Thyas Co. Ltd. (JP) | 2025-06-05 | — | — | US | disclosed |
| CN-119709615-A | Method for producing CD3 positive cells | 国立大学法人京都大学 | 2025-03-28 | — | — | CN | disclosed |
| CN-112567025-B | Method for producing CD3 positive cells | 国立大学法人京都大学 | 2025-01-17 | — | — | CN | disclosed |
| WO-2024242080-A1 | METHOD FOR PRODUCING CELL POPULATION CONTAINING CD4 SINGLE POSITIVE HELPER T CELLS FROM PLURIPOTENT STEM CELLS | 国立大学法人京都大学 | 2024-11-28 | — | — | WO | disclosed |
| CN-114010641-A | Methods for treating neurological disorders | 爱普制药有限责任公司 | 2022-02-08 | — | — | CN | disclosed |
| WO-2021086912-A1 | COMBINED PIKFYVE AND P38 MAP KINASE INHIBITION FOR TREATING CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-05-06 | — | — | WO | disclosed |
| EP-3024926-B1 | GENERATING DEFINITIVE ENDODERM AND PANCREATIC PROGENITOR CELLS | THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2021-03-03 | — | — | EP | disclosed |
| WO-2018140791-A1 | METHODS OF ENHANCING ENGRAFTMENT ACTIVITY OF HEMATOPOIETIC STEM CELLS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2018-08-02 | — | — | WO | disclosed |
| EP-3024926-A1 | GENERATING DEFINITIVE ENDODERM AND PANCREATIC PROGENITOR CELLS | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2016-06-01 | — | — | EP | disclosed |
| WO-2015013653-A1 | GENERATING DEFINITIVE ENDODERM AND PANCREATIC PROGENITOR CELLS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-01-29 | — | — | WO | disclosed |
| EP-0988301-B1 | IMIDAZOLYL-CYCLIC ACETALS | AVENTIS PHARMA LTD (GB) | 2006-08-09 | — | — | EP | disclosed |
| US-6989395-B2 | Imidazolyl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2006-01-24 | — | — | US | disclosed |
| US-20040038991-A1 | Imidazolyl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2004-02-26 | — | — | US | disclosed |
| US-6602877-B1 | Imidazolyl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2003-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038991-A1 | Imidazolyl-cyclic acetals | CBR1, LBR, CBR3 | MAPK13 1610/4885MAPK12 2766/4885MAPK11 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.